Inclusion Criteria:

- Histologically confirmed diagnosis of melanoma with measurable disease

- Patients with stage IV or unresectable advanced melanoma

- Age at least 16 years.

- ECOG performance status of 0-1

- Life expectancy > 3 months

- Adequate major organ function to tolerate therapy, as defined by:

- Total bilirubin 2.0 mg/dL.

- Creatinine 1.8 mg/dL.

- WBC 3,000/mm3.

- Platelet count 100,000/mm3.

- Patients 50 years of age with one or more cardiac risk factors must demonstrate
normal exercise stress test, stress thallium test, or comparable cardiac ischemia
evaluation

- Left ventricular ejection fraction > 40%

- Women of childbearing age must agree to use barrier method birth control and
demonstrate a negative pregnancy test prior to initiation of protocol therapy.
Periodic negative urine pregnancy tests will also be required.

- Patients must give written informed consent

Exclusion Criteria:

- No prior HD- IL-2 for stage IV/unresectable advanced disease. Prior low dose IL-2 is
allowed.

- No more than 2 prior chemotherapy regimens are allowed.

- No active CNS metastases. Treated CNS metastases without recurrence or progression
for > 8 weeks are allowed.

- No concurrent use of systemic corticosteroids

- Pregnant and/or lactating are excluded

- No concurrent antineoplastic treatments, including chemotherapy, biologic response
modifiers, radiation, vaccines, or other experimental therapies.

- No treatment for melanoma within the previous 4 weeks.